|Back to main|
Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
3/20/2013 4:30:00 PM
) recently announced a strategic deal with Nordic Bioscience
Clinical Development A/S for its pipeline candidate, sprifermin
(recombinant human FGF-18). Sprifermin is being developed for
osteoarthritis (OA) of the knee.
We are positive on Merck KGaA's decision to collaborate with Nordic Bioscience. Nordic Bioscience's expertise in OA would be a major boost for sprifermin's development.
As per information provided by the World Health Organization (WHO), osteoarthritis of the knee affects more than 5% of the people over 40 years in developed countries, or more than 30 million people.
BRISTOL-MYERS (BMY): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
MERCK KGAA (MKGAF): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research